Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

By Wong Doo Nicole  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

High-dose Melphalan Followed by Autograft Employing Non-cryopreserved Peripheral Blood Progenitor Cells in Children

By Jones N.   Williams D.   Broadbent V.   Jestice K.   Boraks P.   Scott M.   Ager S.   Marcus R.  

European Journal of Cancer, Vol. 32, Iss. 11, 1996-10 ,pp. : 1938-1942

Elsevier

Access to resources Recommend Favorite

Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning

By Russell Nigel   Bessell Eric   Stainer Claire   Haynes Andrew   Das-Gupta Emma   Byrne Jenny  

Acta Oncologica, Vol. 39, Iss. 7, 2000-11 ,pp. : 837-841

Informa Healthcare

Access to resources Recommend Favorite

Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support

By Gulbrandsen N.   Wisløff F.   Brinch L.   Carlson K.   Dahl I.M.   Gimsing P.   Hippe E.   Hjorth M.   Knudsen L.M.   Lamvik J.   Lenhoff S.   Løfvenberg E.   Nesthus I.   Lanng Nielsen J.   Turesson I.   Westin J.  

Medical Oncology, Vol. 18, Iss. 1, 2001-03 ,pp. : 65-77

Humana Press, Inc

Access to resources Recommend Favorite

Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment

By Sonneveld P.   Segeren C.M.  

European Journal of Cancer, Vol. 39, Iss. 1, 2003-01 ,pp. : 9-18

Elsevier

Access to resources Recommend Favorite